<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310332</url>
  </required_header>
  <id_info>
    <org_study_id>QIPS propensity score matching</org_study_id>
    <nct_id>NCT04310332</nct_id>
  </id_info>
  <brief_title>1L- vs. 4L-PEG for Bowel Preparation Among Inpatients.</brief_title>
  <official_title>1L- vs. 4L-Polyethylene Glycol for Bowel Preparation Before Colonoscopy Among Inpatients: a Propensity Score-matching Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and aims: Inpatients are at high risk for inadequate colon cleansing. Experts
      recommend 4L-polyethylene-glycol (PEG) solution because of its effectiveness and safety
      profile. A higher colon cleansing adequacy rate for a hyperosmolar 1L-PEG plus ascorbate prep
      has been recently reported in an observational study among more than 1,000 inpatients. Thus,
      the present study is aimed at determining whether 1L-PEG outperforms 4L-PEG among inpatients,
      through a propensity score-matching between the two groups in order to correct for
      confounders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall colon cleansing efficacy</measure>
    <time_frame>Outcome will be assessed during colonoscopy</time_frame>
    <description>Proportion of patients with adequate colon cleansing (Boston Bowel Preparation Score ≥2 for each colon segment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right colon cleansing efficacy</measure>
    <time_frame>Outcome is assessed during colonoscopy</time_frame>
    <description>Proportion of patients with adequate colon cleansing in the right colon (Boston Bowel Preparation Score ≥2 in the right colon)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (serum sodium imbalance)</measure>
    <time_frame>within 12 hours before starting bowel prep intake; the morning of the day after the colonoscopy</time_frame>
    <description>Degree of serum sodium shift (mmol/L) before and after bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (serum potassium imbalance)</measure>
    <time_frame>within 12 hours before starting bowel prep intake; the morning of the day after the colonoscopy</time_frame>
    <description>Degree of serum potassium shift (mmol/L) before and after bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (serum calcium imbalance)</measure>
    <time_frame>within 12 hours before starting bowel prep intake; the morning of the day after the colonoscopy</time_frame>
    <description>Degree of serum calcium shift (mg/dL) before and after bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (serum magnesium imbalance)</measure>
    <time_frame>within 12 hours before starting bowel prep intake; the morning of the day after the colonoscopy</time_frame>
    <description>Degree of serum magnesium shift (mg/dL) before and after bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (serum creatinine imbalance)</measure>
    <time_frame>within 12 hours before starting bowel prep intake; the morning of the day after the colonoscopy</time_frame>
    <description>Degree of serum creatinine shift (mg/dL) before and after bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (glomerular filtration rate change)</measure>
    <time_frame>within 12 hours before starting bowel prep intake; the morning of the day after the colonoscopy</time_frame>
    <description>Degree of change in glomerular filtration rate (mL/min/1.73 m2), before and after bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (hematocrit change)</measure>
    <time_frame>within 12 hours before starting bowel prep intake; the morning of the day after the colonoscopy</time_frame>
    <description>Degree of change in hematocrit (%), before and after bowel preparation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1004</enrollment>
  <condition>Colonoscopy</condition>
  <condition>Hospitalized Patients</condition>
  <condition>Bowel Preparation</condition>
  <arm_group>
    <arm_group_label>1L-PEG</arm_group_label>
    <description>Hospitalized patients who are prescribed colonoscopy with 1L-polyethylene glycole (PEG) plus ascorbic acid as bowel preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4L-PEG</arm_group_label>
    <description>Hospitalized patients who are prescribed colonoscopy with 4L-polyethylene glycole (PEG) as bowel preparation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1L-PEG</intervention_name>
    <description>The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.
Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.</description>
    <arm_group_label>1L-PEG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4L-PEG</intervention_name>
    <description>The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.
Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational.</description>
    <arm_group_label>4L-PEG</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients who are scheduled a colonoscopy as inpatients.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult inpatients scheduled for colonoscopy for any indication within the normal
             process of care.

        Exclusion Criteria:

          -  patients who underwent emergency or elective therapeutic colonoscopies (e.g.
             polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection)

          -  patients who underwent bowel preparation outside the hospital
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Endoscopy Unit, Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOSD Gastroenterologia ed Endoscopia Digestiva, Azienda USL di Modena</name>
      <address>
        <city>Carpi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit, Valduce Hospital</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit of Gastroenterology and Digestive Endoscopy, Forli-Cesena Hospital, AUSL Romagna</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Endoscopy Unit, Centro Traumatologico-Ortopedico Hospital</name>
      <address>
        <city>Iglesias</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, ASST Rhodense, Rho and Garbagnate Milanese Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Digestive Endoscopy Unit, Ospedale Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Gastroenterology and Hepatology Unit, &quot;Guglielmo da Saliceto&quot; Hospital</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit, S. Maria delle Croci Hospital</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Lorenzo Fuccio</investigator_full_name>
    <investigator_title>Professor of Gastroenterology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

